Clinical Trial Update: Vismodegib After Stem Cell Transplant in Treating Patients With High-Risk First Remission or Relapsed Multiple Myeloma [Phase 1]

View source ↗

Summary

Phase 1 trial update of vismodegib after stem cell transplant in high-risk or relapsed multiple myeloma; the study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Vismodegib (Vismodegib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma | Phase 1 | Status: COMPLETED